146 related articles for article (PubMed ID: 9048348)
21. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
[TBL] [Abstract][Full Text] [Related]
22. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
Allegra V; Martimbianco L; Vasile A
Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
[TBL] [Abstract][Full Text] [Related]
23. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
24. Intravenous iron dextran and erythropoietin use in pediatric hemodialysis patients.
Greenbaum LA; Pan CG; Caley C; Nelson T; Sheth KJ
Pediatr Nephrol; 2000 Sep; 14(10-11):908-11. PubMed ID: 10975297
[TBL] [Abstract][Full Text] [Related]
25. Effect of hyperparathyroidism on response to erythropoietin in children on dialysis.
Belsha CW; Berry PL
Pediatr Nephrol; 1998 May; 12(4):298-303. PubMed ID: 9655362
[TBL] [Abstract][Full Text] [Related]
26. Low-dose intravenous iron administration in chronic hemodialysis patients treated with recombinant human erythropoietin.
Harmankaya O; Eran A
Ren Fail; 2002 Mar; 24(2):245-7. PubMed ID: 12071600
[TBL] [Abstract][Full Text] [Related]
27. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.
Chang CH; Chang CC; Chiang SS
Clin Nephrol; 2002 Feb; 57(2):136-41. PubMed ID: 11863124
[TBL] [Abstract][Full Text] [Related]
28. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin.
Jensen JD; Madsen JK; Jensen LW
Eur J Clin Pharmacol; 1996; 50(3):171-7. PubMed ID: 8737755
[TBL] [Abstract][Full Text] [Related]
29. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients.
Tomson CR; Feehally J; Walls J
Nephrol Dial Transplant; 1992; 7(2):129-32. PubMed ID: 1314972
[TBL] [Abstract][Full Text] [Related]
30. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
31. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
32. Anemia and carnitine supplementation in hemodialyzed patients.
Kletzmayr J; Mayer G; Legenstein E; Heinz-Peer G; Leitha T; Hörl WH; Kovarik J
Kidney Int Suppl; 1999 Mar; 69():S93-106. PubMed ID: 10084293
[TBL] [Abstract][Full Text] [Related]
33. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Acharya VN; Sinha DK; Almeida AF; Pathare AV
J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
[TBL] [Abstract][Full Text] [Related]
34. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients.
Walter J; Gål J; Taraba I
Artif Organs; 1995 Jan; 19(1):76-80. PubMed ID: 7741644
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group.
Weiss LG; Clyne N; Divino Fihlho J; Frisenette-Fich C; Kurkus J; Svensson B
Nephrol Dial Transplant; 2000 Dec; 15(12):2014-9. PubMed ID: 11096148
[TBL] [Abstract][Full Text] [Related]
36. [Italian study on the treatment of anaemia in chronic dialysis patients switched over to less frequent doses of darbepoetin from human recombinant erythropoietin (rHuEPO)].
Del Vecchio L; Villa G; Carraro G; Morosetti M; Pedrini L; Adorati Menegato M; Amato M; Mauro MM; Borgatti P; Malberti F; Marai P; Locatelli F;
G Ital Nefrol; 2004; 21(3):259-66. PubMed ID: 15285005
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy and safety of long-term erythropoietin therapy in chronic hemodialysis patients with renal anemia].
Ohkubo M; Ishimitsu T; Kawaguchi T; Abe M; Yagi S
Nihon Jinzo Gakkai Shi; 1993 Feb; 35(2):171-7. PubMed ID: 8315880
[TBL] [Abstract][Full Text] [Related]
38. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin.
Watson AJ; Gimenez LF; Cotton S; Walser M; Spivak JL
Am J Med; 1990 Oct; 89(4):432-5. PubMed ID: 2220877
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous erythropoietin therapy: efficacy and economic implications.
Kaufman JS
Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S147-51. PubMed ID: 9892382
[TBL] [Abstract][Full Text] [Related]
40. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
